$INSM

Flammer Martina M.D. sold $1.4M of INSM

Flammer Martina M.D. (Chief Medical Officer) sold 12,302 shares of INSMED Inc (INSM) at an average of $109.98 ($109.02–$110.60, $1.35M total) across 2 trades on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Flammer Martina M.D.
Published Jul 8, 2026, 8:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INSM
Neutral
high confidence
Mentioned
$INSM
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The newest fact is the CMO’s open-market sale size, price range, and post-transaction holdings, with explicit 10b5-1 plan context.

02

Market read

This provides a fresh, auditable datapoint on insider selling activity, but it does not introduce new company fundamentals.

03

What to watch

Traders may over-weight insider sales; without accompanying buy transactions, guidance, or business updates, the signal is mostly sentiment-level.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-07-08 after the 2026-07-06 sale execution.

Background

The article is an SEC Form 4 insider transaction disclosure for INSMED Inc.

Company-level read

Ticker impact

$INSMNeutralHigh confidence
Context

INSMED CMO Flammer Martina sold about 12,302 shares in open-market transactions totaling about $1.35M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider sale with stated 10b5-1 pre-arranged plan, and it provides no new operational, financial, or regulatory information beyond the transaction details.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • INSMED Inc

    Company whose insider transaction is disclosed on SEC Form 4.

  • Flammer Martina M.D.

    Chief Medical Officer who executed the open-market sale under a 10b5-1 plan.

Related articles

$INSMMed

Insmed Q2 Earnings Call Highlights

Insmed (INSM) reported Q2 call highlights. It narrowed BRINSUPRI gross-to-net guidance to mid-to-high 20% and raised global peak sales to over $7B. It expects ARIKAYCE expansion filings in the U.S. and Japan, with Japan application in 2H26. TPIP peak sales estimate rose to over $6B. Cash was about $1.2B; it targets cash-flow positivity in 2027.